Alzheimer’s Blood Tests Are Moving Closer to Everyday Care: What They Can Tell You, and What They Still Can’t

Practical takeaway: Alzheimer’s blood tests are getting closer to everyday care in the United States, but they are not simple yes-or-no answers. The most important current step is the FDA’s October 8, 2025 clearance of Roche’s Elecsys Phospho-Tau (181P) Plasma test for use in primary care as part of an initial evaluation of cognitive decline. ([accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K252163))

That matters because blood testing is less invasive than a spinal tap and easier to reach than an amyloid PET scan. But it also matters because readers could easily misunderstand what these tests can do. Right now, the cleared Roche test is for adults age 55 and older who already have signs, symptoms, or complaints of cognitive decline. It is not a general screening test for healthy people who are simply worried about future risk. ([accessdata.fda.gov](https://www.accessdata.fda.gov/cdrh_docs/reviews/K252163.pdf))

Why Alzheimer’s blood tests are back in the spotlight

Blood-based biomarker testing has been moving quickly. The FDA cleared Fujirebio’s first blood test for Alzheimer’s biomarkers in May 2025, and Roche’s October 2025 clearance pushed the field closer to routine clinic use by bringing a pTau181-based test into primary care. JAMA Medical News reported that primary care clinicians have been asking a basic real-world question ever since: what does this test actually mean for a patient sitting in front of them? ([apnews.com](https://apnews.com/article/ad3cffe0bd540accf47e8ee105b439a9))

What the Roche primary-care test actually does

According to the FDA decision summary, Elecsys Phospho-Tau (181P) Plasma is intended to aid the initial assessment of Alzheimer’s disease and other causes of cognitive decline in adults 55 and older who present in primary care with memory or thinking concerns. The FDA also says the result must be interpreted with other clinical information. A negative result is meant to line up with a negative amyloid PET scan and a lower likelihood that amyloid pathology is causing the person’s symptoms. A positive result, by contrast, may not line up with a positive amyloid PET scan and should lead to more evaluation. ([accessdata.fda.gov](https://www.accessdata.fda.gov/cdrh_docs/reviews/K252163.pdf))

That makes this, in practical terms, much more of a rule-out tool than a stand-alone rule-in test. The FDA also says the assay was not established for predicting who will develop dementia later or for monitoring response to treatment. ([accessdata.fda.gov](https://www.accessdata.fda.gov/cdrh_docs/reviews/K252163.pdf))

What a negative result means, and what a positive result does not mean

The Roche numbers are the part families should understand most clearly. In the FDA-reviewed primary-care study, 312 people had evaluable results. Among 142 people with a negative blood test, 139 also had a negative amyloid PET scan. That translated to a negative predictive value of 97.9%. In plain language: in this study, a negative result was usually reassuring. ([accessdata.fda.gov](https://www.accessdata.fda.gov/cdrh_docs/reviews/K252163.pdf))

A positive result was much less definitive. Of 170 people with a positive blood test, only 38 also had a positive amyloid PET scan. That produced a positive predictive value of 22.4%. In other words, many positive blood-test results did not match a positive PET scan in this primary-care population, so a positive result should not be read as proof that someone has Alzheimer’s disease. ([accessdata.fda.gov](https://www.accessdata.fda.gov/cdrh_docs/reviews/K252163.pdf))

Why experts still want a full workup

The FDA, the Alzheimer’s Association guideline, and public-health sources all point in the same direction: blood biomarkers are pieces of the puzzle, not the whole puzzle. The Association’s 2025 clinical practice guideline was written for specialized memory-care settings, not every primary care office. It says blood-based biomarker tests with at least 90% sensitivity and 75% specificity can be used as triage tests, while only tests with at least 90% sensitivity and 90% specificity can substitute for amyloid PET or cerebrospinal-fluid testing in specialized care. The same guideline warns that many commercially available tests do not meet those thresholds and that tests are not interchangeable. ([aaic.alz.org](https://aaic.alz.org/releases-2025/clinical-practice-guideline-blood-based-biomarkers.asp))

The guideline also says these tests do not replace a comprehensive clinical evaluation. That usually means putting symptoms, daily functioning, medical history, medicines, exam findings, and other testing together. MedlinePlus notes that PET or a lumbar puncture may sometimes be needed to confirm Alzheimer’s disease, and CT or MRI may be used to look for other causes of cognitive decline. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40729527/))

Who should ask about testing now, and who should not

Families should think about asking a clinician about testing when a person 55 or older has new or worsening memory or thinking problems that are affecting daily life, such as repeating questions, getting lost in familiar places, trouble handling bills or medicines, or noticeable changes in judgment or function. CDC says some changes in memory and thinking can happen with aging, but Alzheimer’s is not a normal part of aging. ([cdc.gov](https://www.cdc.gov/alzheimers-dementia/about/alzheimers.html))

People without symptoms should not treat these tests as casual screening tools or direct-to-consumer answers. The cleared Roche use is limited to symptomatic adults in clinical care, the test is prescription-only, and expert guidance says results should be ordered and interpreted by a health professional in context. ([accessdata.fda.gov](https://www.accessdata.fda.gov/cdrh_docs/reviews/K252163.pdf))

Access could improve, but follow-up still matters

One reason clinicians are interested in blood testing is access. Compared with PET imaging and spinal-fluid tests, the Alzheimer’s Association says blood-based biomarkers are typically less costly, more accessible, and more acceptable to patients. That could help more people get evaluated earlier, especially outside specialty centers. But real access still depends on whether a patient can get a careful cognitive evaluation, follow-up testing when needed, and referral pathways that make sense locally. ([aaic.alz.org](https://aaic.alz.org/releases-2025/clinical-practice-guideline-blood-based-biomarkers.asp))

What is next in 2026, and why it is still too early to overpromise

Research is still moving fast. In a February 27, 2026 NIH news release, NIH described a Nature Aging study on a new class of blood-based Alzheimer’s biomarkers that measure structural changes in proteins and may reveal information not captured by standard blood tests. That is a useful sign that the science is advancing, but it is not the same thing as saying routine screening for healthy adults is ready. ([nih.gov](https://www.nih.gov/news-events/news-releases/study-measuring-changes-protein-structure-establishes-new-class-alzheimers-biomarkers))

What this means for readers

If your family is worried about memory changes, the main question is not whether you can get just any Alzheimer’s blood test. The better questions are: Is this symptom pattern concerning? Is a blood biomarker test appropriate in this setting? If the result is negative, what other causes should be checked? If it is positive, what follow-up testing or referral comes next? And could medicines, depression, stroke, sleep problems, or another condition explain the symptoms instead? A blood test may help speed the path, but it still should not replace a careful medical evaluation. ([accessdata.fda.gov](https://www.accessdata.fda.gov/cdrh_docs/reviews/K252163.pdf))

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.